FDA expands approval of ixekizumab for nonradiographic axial spondyloarthritis
June 01, 2020
The FDA expands approval of ixekizumab for nonradiographic axial spondyloarthritis; Atul Deodhar, M.D., says: “Today’s FDA approval provides patients with a much-needed treatment option targeting IL-17A to improve the signs and symptoms of nr-axSpA."